1. Protein Tyrosine Kinase/RTK Neuronal Signaling GPCR/G Protein
  2. DYRK 5-HT Receptor
  3. Harmine

Harmine  (Synonyms: Telepathine)

Cat. No.: HY-N0737A Purity: 99.88%
SDS COA Handling Instructions

Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM.

For research use only. We do not sell to patients.

Harmine Chemical Structure

Harmine Chemical Structure

CAS No. : 442-51-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 66 In-stock
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Solid
100 mg USD 30 In-stock
500 mg USD 60 In-stock
1 g USD 95 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 22 publication(s) in Google Scholar

Other Forms of Harmine:

Top Publications Citing Use of Products

    Harmine purchased from MedChemExpress. Usage Cited in: Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 15;79(Pt B):258-267.  [Abstract]

    Representative images showing the restoration effect of Harmine on CUS-induced decrease in hippocampal DCX protein expressions. The Fluoxetine administration (20 mg/kg) is used as a positive control, and all data are shown as mean±SEM.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM[1].

    IC50 & Target[1][2]

    5-HT2A Receptor

    397 nM (Ki)

    DYRK1A

     

    Cellular Effect
    Cell Line Type Value Description References
    769-P IC50
    48.9 μM
    Compound: 7
    Cytotoxicity against human renal carcinoma 769-P cells assessed as reduction in optical density by MTT assay
    Cytotoxicity against human renal carcinoma 769-P cells assessed as reduction in optical density by MTT assay
    [PMID: 23279863]
    A-375 IC50
    72.5 μM
    Compound: 7
    Cytotoxicity against human malignant melanoma A375 cells assessed as reduction in optical density by MTT assay
    Cytotoxicity against human malignant melanoma A375 cells assessed as reduction in optical density by MTT assay
    [PMID: 23279863]
    A549 IC50
    17.12 μM
    Compound: Harmine
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 34425477]
    A549 IC50
    42.25 μM
    Compound: Harmine
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    [PMID: 27397495]
    A549 IC50
    5.23 μM
    Compound: HM
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35341920]
    A549 IC50
    5.89 μM
    Compound: Harmine
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    [PMID: 31227365]
    A549 IC50
    52.56 μM
    Compound: 6; Harmine
    Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
    10.1039/C5MD00581G
    A549 IC50
    7.76 μM
    Compound: Har
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 29129513]
    Bel-7402 IC50
    54 μM
    Compound: 1
    Cytotoxicity against human Bel7402 cells by MTT assay
    Cytotoxicity against human Bel7402 cells by MTT assay
    [PMID: 23291116]
    Bel-7402 IC50
    54 μM
    Compound: Harmine
    Cytotoxicity against human Bel7402 cells by MTT assay
    Cytotoxicity against human Bel7402 cells by MTT assay
    [PMID: 18462839]
    BGC-823 IC50
    15.63 μM
    Compound: HM
    Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35341920]
    BGC-823 IC50
    63.2 μM
    Compound: 7
    Cytotoxicity against human gastric carcinoma BGC823 cells assessed as reduction in optical density by MTT assay
    Cytotoxicity against human gastric carcinoma BGC823 cells assessed as reduction in optical density by MTT assay
    [PMID: 23279863]
    BGC-823 IC50
    68 μM
    Compound: 1
    Cytotoxicity against human BGC823 cells by MTT assay
    Cytotoxicity against human BGC823 cells by MTT assay
    [PMID: 23291116]
    BGC-823 IC50
    68 μM
    Compound: Harmine
    Cytotoxicity against human BGC823 cells by MTT assay
    Cytotoxicity against human BGC823 cells by MTT assay
    [PMID: 18462839]
    COLO 205 IC50
    26 μM
    Compound: Harmine
    Antiproliferative activity against human COLO205 cells after 24 hrs by MTT assay
    Antiproliferative activity against human COLO205 cells after 24 hrs by MTT assay
    [PMID: 22365759]
    COLO 205 IC50
    46 μM
    Compound: Harmine
    Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay
    Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay
    [PMID: 22202437]
    COLO 205 IC50
    8 μM
    Compound: Harmine
    Cytotoxicity against human COLO205 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human COLO205 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 28216402]
    COLO 205 IC50
    8 μM
    Compound: Harmine
    Antiproliferative activity against human COLO205 cells by MTT assay
    Antiproliferative activity against human COLO205 cells by MTT assay
    [PMID: 22749421]
    DU-145 IC50
    12.02 μM
    Compound: Har
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
    [PMID: 29129513]
    DU-145 IC50
    9.63 μM
    Compound: Harmine
    Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    [PMID: 31227365]
    HCT-116 IC50
    43.8 μM
    Compound: Harmine
    Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay
    [PMID: 30851694]
    HCT-116 IC50
    43.8 μM
    Compound: Harmine
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
    [PMID: 35272009]
    HCT-116 IC50
    46.7 μM
    Compound: Harmine
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 30108831]
    HCT-116 IC50
    46.7 μM
    Compound: Harmine
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 29288941]
    HCT-116 IC50
    46.7 μM
    Compound: Harmine
    Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 26555243]
    HCT-116 IC50
    6.94 μM
    Compound: HM
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35341920]
    HEK293 IC50
    0.4 μM
    Compound: Hrm
    Inhibition of tetracycline-inducible EGFP-DYRK1A (unknown origin) expressed in HEK293 cells coexpressing full length human EGFP-tau protein assessed as reduction in tau-Thr212 phosphorylation incubated overnight by immunofluorescence assay
    Inhibition of tetracycline-inducible EGFP-DYRK1A (unknown origin) expressed in HEK293 cells coexpressing full length human EGFP-tau protein assessed as reduction in tau-Thr212 phosphorylation incubated overnight by immunofluorescence assay
    [PMID: 26896709]
    HeLa IC50
    > 10 μM
    Compound: Harmine
    Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis
    Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis
    [PMID: 26555243]
    HeLa IC50
    16.21 μM
    Compound: Har
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 29129513]
    HeLa IC50
    60 μM
    Compound: 1
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 23291116]
    HeLa IC50
    60 μM
    Compound: Harmine
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    [PMID: 18462839]
    HeLa IC50
    8 μM
    Compound: Harmine
    Cytotoxicity against human HeLa cells after 5 days by MTT assay
    Cytotoxicity against human HeLa cells after 5 days by MTT assay
    [PMID: 30193214]
    HeLa IC50
    85.28 μM
    Compound: 6; Harmine
    Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
    10.1039/C5MD00581G
    HeLa IC50
    9.66 μM
    Compound: Harmine
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
    [PMID: 31227365]
    HepG2 IC50
    > 250 μM
    Compound: HAR
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay
    [PMID: 35551033]
    HepG2 IC50
    > 250 μM
    Compound: HAR
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay
    [PMID: 34274829]
    HepG2 IC50
    > 250 μM
    Compound: Harmine
    Cytotoxicity against human HepG2 cells measured after 24 hrs by neutral red assay
    Cytotoxicity against human HepG2 cells measured after 24 hrs by neutral red assay
    [PMID: 31812035]
    HepG2 IC50
    16.8 μM
    Compound: HM
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35341920]
    HepG2 IC50
    46 μM
    Compound: 1
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 23291116]
    HepG2 IC50
    46 μM
    Compound: Harmine
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 18462839]
    HepG2 IC50
    49.96 μM
    Compound: Harmine
    Antiproliferative activity against human HepG2 cells by MTT assay
    Antiproliferative activity against human HepG2 cells by MTT assay
    [PMID: 32787089]
    HepG2 IC50
    51.2 μM
    Compound: Harmine
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 30108831]
    HepG2 IC50
    51.2 μM
    Compound: Harmine
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 29288941]
    HepG2 IC50
    53.6 μM
    Compound: Harmine
    Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
    [PMID: 30851694]
    HepG2 IC50
    53.6 μM
    Compound: Harmine
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 31120744]
    HGC-27 IC50
    3.52 μM
    Compound: Harmine
    Antiproliferative activity against human HGC27 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HGC27 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31546197]
    HL-60 IC50
    62.45 μM
    Compound: 6; Harmine
    Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay
    10.1039/C5MD00581G
    HL-60 IC50
    7.55 μM
    Compound: 11
    Antiproliferative activity against human HL60 cells by tryphan blue assay
    Antiproliferative activity against human HL60 cells by tryphan blue assay
    [PMID: 28128938]
    Hs 683 IC50
    37 μM
    Compound: 1
    Growth inhibition of human Hs 683 cells after 3 days by MTT assay
    Growth inhibition of human Hs 683 cells after 3 days by MTT assay
    [PMID: 22770529]
    Hs 683 IC50
    37 μM
    Compound: 1, Harmine
    Cytostatic activity against human Hs683 cells after 72 hrs by videomicroscopy
    Cytostatic activity against human Hs683 cells after 72 hrs by videomicroscopy
    [PMID: 25747498]
    HT-22 IC50
    56.5 μM
    Compound: 14
    Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
    [PMID: 36876904]
    HT-29 IC50
    3.52 μM
    Compound: Harmine
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31546197]
    HT-29 IC50
    41.8 μM
    Compound: Harmine
    Antiproliferative activity against human HT-29 cells by MTT assay
    Antiproliferative activity against human HT-29 cells by MTT assay
    [PMID: 32787089]
    IMR-32 IC50
    38 μM
    Compound: Harmine
    Antiproliferative activity against human IMR32 cells after 24 hrs by MTT assay
    Antiproliferative activity against human IMR32 cells after 24 hrs by MTT assay
    [PMID: 22365759]
    IMR-32 IC50
    68 μM
    Compound: Harmine
    Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay
    Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay
    [PMID: 22202437]
    K562 IC50
    14 μM
    Compound: Harmine
    Cytotoxicity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 28216402]
    K562 IC50
    14 μM
    Compound: Harmine
    Antiproliferative activity against human K562 cells by MTT assay
    Antiproliferative activity against human K562 cells by MTT assay
    [PMID: 22749421]
    K562 IC50
    32 μM
    Compound: Harmine
    Antiproliferative activity against human K562 cells after 24 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 24 hrs by MTT assay
    [PMID: 22365759]
    K562 IC50
    45 μM
    Compound: Harmine
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    [PMID: 22516283]
    K562 IC50
    45 μM
    Compound: Harmine
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    [PMID: 22202437]
    KB IC50
    57.8 μM
    Compound: 7
    Cytotoxicity against human epidermoid carcinoma of the nasopharynx KB cells assessed as reduction in optical density by MTT assay
    Cytotoxicity against human epidermoid carcinoma of the nasopharynx KB cells assessed as reduction in optical density by MTT assay
    [PMID: 23279863]
    L02 IC50
    25.09 μM
    Compound: HM
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35341920]
    LoVo IC50
    53.2 μM
    Compound: Harmine
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
    [PMID: 30108831]
    LoVo IC50
    53.2 μM
    Compound: Harmine
    Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 26555243]
    MCF7 IC50
    10.78 μM
    Compound: Har
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 29129513]
    MCF7 IC50
    15.27 μM
    Compound: HM
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 35341920]
    MCF7 IC50
    16.94 μM
    Compound: Harmine
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 33744443]
    MCF7 IC50
    3.52 μM
    Compound: Harmine
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 31546197]
    MCF7 IC50
    68.33 μM
    Compound: Harmine
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    [PMID: 27397495]
    MCF7 IC50
    70.7 μM
    Compound: 6; Harmine
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    10.1039/C5MD00581G
    MCF7 IC50
    72 μM
    Compound: Harmine
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    [PMID: 18462839]
    MDA-MB-231 IC50
    21.91 μM
    Compound: Harmine
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
    [PMID: 33744443]
    MDA-MB-231 IC50
    32 μM
    Compound: Harmine
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
    [PMID: 28216402]
    MDA-MB-231 IC50
    32 μM
    Compound: Harmine
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells by MTT assay
    [PMID: 22749421]
    MDA-MB-231 IC50
    54 μM
    Compound: Harmine
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay
    [PMID: 22516283]
    MDA-MB-231 IC50
    54 μM
    Compound: Harmine
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    [PMID: 22202437]
    MDA-MB-435 IC50
    > 100 μM
    Compound: Harmine
    Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 1 day by MTT assay
    Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 1 day by MTT assay
    [PMID: 33813152]
    MDA-MB-435 IC50
    17.1 μM
    Compound: Harmine
    Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay
    Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay
    [PMID: 33813152]
    MDCK-II GI50
    2.3 μM
    Compound: Harmine
    Cytotoxicity against wild-type MDCK2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against wild-type MDCK2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 27280693]
    MDCK-II GI50
    2.42 μM
    Compound: Harmine
    Cytotoxicity against MDCK2 cells expressing human ABCG2 assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against MDCK2 cells expressing human ABCG2 assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 27280693]
    NCI-H2228 IC50
    31.06 μM
    Compound: Harmine
    Antiproliferative activity against human EML4-ALK positive H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human EML4-ALK positive H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    [PMID: 34425477]
    OE33 IC50
    18 μM
    Compound: 1
    Growth inhibition of human OE33 cells after 3 days by MTT assay
    Growth inhibition of human OE33 cells after 3 days by MTT assay
    [PMID: 22770529]
    PC-3 IC50
    3.52 μM
    Compound: Harmine
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 31546197]
    SGC-7901 IC50
    40.82 μM
    Compound: Harmine
    Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    [PMID: 27397495]
    SGC-7901 IC50
    70.36 μM
    Compound: 6; Harmine
    Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay
    10.1039/C5MD00581G
    SK-OV-3 IC50
    74.6 μM
    Compound: 7
    Cytotoxicity against human ovary adenocarcinoma SKOV3 cells assessed as reduction in optical density by MTT assay
    Cytotoxicity against human ovary adenocarcinoma SKOV3 cells assessed as reduction in optical density by MTT assay
    [PMID: 23279863]
    SMMC-7721 IC50
    47.6 μM
    Compound: Harmine
    Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay
    [PMID: 30851694]
    SMMC-7721 IC50
    47.6 μM
    Compound: Harmine
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    [PMID: 31120744]
    SMMC-7721 IC50
    55.3 μM
    Compound: Harmine
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    [PMID: 30108831]
    SMMC-7721 IC50
    55.3 μM
    Compound: Harmine
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
    [PMID: 29288941]
    SMMC-7721 IC50
    59.44 μM
    Compound: Harmine
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
    [PMID: 27397495]
    SW-620 IC50
    42.8 μM
    Compound: Harmine
    Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 26555243]
    T98G IC50
    24 μM
    Compound: 1
    Growth inhibition of human T98G cells after 3 days by MTT assay
    Growth inhibition of human T98G cells after 3 days by MTT assay
    [PMID: 22770529]
    U-373MG ATCC IC50
    32 μM
    Compound: 1
    Growth inhibition of human U373 cells after 3 days by MTT assay
    Growth inhibition of human U373 cells after 3 days by MTT assay
    [PMID: 22770529]
    U-87MG ATCC IC50
    7.2 μM
    Compound: Hrm
    Growth inhibition of human U87MG cells after 4 days by MTT assay
    Growth inhibition of human U87MG cells after 4 days by MTT assay
    [PMID: 26896709]
    In Vitro

    Harmine inhibits tau phosphorylation by DYRK1A by selected DANDYs, with an IC50 of 190 nM[2].Harmine negatively regulates homologous recombination (HR) by interfering Rad51 recruitment, resulting in severe cytotoxicity in hepatoma cells. Furthermore, NHEJ inhibitor Nu7441 markedly sensitizes Hep3B cells to the anti-proliferative effects of Harmine[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    It is shown that brain water content is significantly increased in the TBI group. Treatment with Harmine significantly reduces the tissue water content at 1, 3 and 5 days, compared with the TBI group. Harmine treatment significantly reduces the escape latency at 3 and 5 days, compared with the TBI group. Post-TBI administration of Harmine significantly improves the motor function recovery of the rats at 1, 3 and 5 days following TBI, compared with the TBI group without Harmine treatment. The neuronal survival rate in the Harmine-treated group is significantly increased, compared with the TBI group. Administration of Harmine results in marked elevation in the expression of GLT-1, compared with the TBI group. The administration of Harmine significantly reduces the expression of caspase 3, compared with the TBI group[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    212.25

    Formula

    C13H12N2O

    CAS No.
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    CC1=NC=CC2=C1NC3=C2C=CC(OC)=C3

    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 30 mg/mL (141.34 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.7114 mL 23.5571 mL 47.1143 mL
    5 mM 0.9423 mL 4.7114 mL 9.4229 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (11.78 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (11.78 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.88%

    References
    Animal Administration
    [4]

    Rats[4]
    A total of 150 male Sprague-Dawley rats (age, 10-12 weeks; weighing, 280-320 g; are used in the present study. The rats are randomly divided into three groups: Sham-operated group (sham; n=15); the TBI group (TBI; n=35) and the TBI + Harmine-treated group (Harmine; n=35). Harmine is administered immediately following TBI (i.p, 30 mg/kg per day) for up to 5 days. The sham and TBI groups receive equal volumes of 0.9% saline solution (i.p.). The rats are grouped as follows for examination of behavioral recovery: Sham, n=3; TBI, n=7; and Harmine, n=7. Following TBI, the NSS is evaluated at 1, 3 and 5 days. Each rat is assessed by an observer who is blinded to the animal treatment[4].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 4.7114 mL 23.5571 mL 47.1143 mL 117.7856 mL
    5 mM 0.9423 mL 4.7114 mL 9.4229 mL 23.5571 mL
    10 mM 0.4711 mL 2.3557 mL 4.7114 mL 11.7786 mL
    15 mM 0.3141 mL 1.5705 mL 3.1410 mL 7.8524 mL
    20 mM 0.2356 mL 1.1779 mL 2.3557 mL 5.8893 mL
    25 mM 0.1885 mL 0.9423 mL 1.8846 mL 4.7114 mL
    30 mM 0.1570 mL 0.7852 mL 1.5705 mL 3.9262 mL
    40 mM 0.1178 mL 0.5889 mL 1.1779 mL 2.9446 mL
    50 mM 0.0942 mL 0.4711 mL 0.9423 mL 2.3557 mL
    60 mM 0.0785 mL 0.3926 mL 0.7852 mL 1.9631 mL
    80 mM 0.0589 mL 0.2945 mL 0.5889 mL 1.4723 mL
    100 mM 0.0471 mL 0.2356 mL 0.4711 mL 1.1779 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Harmine
    Cat. No.:
    HY-N0737A
    Quantity:
    MCE Japan Authorized Agent: